La cadena de opciones muestra datos clave de las opciones de acciones de Oriental Rise Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Oriental Rise Holdings..

Oriental Rise Holdings (NASDAQ:ORIS) Bolsa, Cadena de Opciones

Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.

Oriental Rise Holdings Limited - Ordinary Shares

Oriental Rise Holdings Ltd

Citigroup analyst Ariel Rosa maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $149 to $123.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on United Parcel Service, Lowers Price Target to $123

&nbsp;
First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation
In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery versus placebo across multiple time points and clinical efficacy measures. The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being in a better state of health than placebo at Week 8 (p=0.0058).
Highlights from the oral presentation at AAN include:
<ul>
<li>New efficacy findings consistently demonstrated rapid recovery and durable benefits of tanruprubart across muscle strength, mobility and disability measures:
	&nbsp;
<ul>
<li>At Week 1, treated patients rapidly gained motor function and were 14-fold more likely to perform the Timed Up and Go (TUG) test, a standardized measure of mobility, balance and lower limb capacity
		&nbsp;</li>
<li>At Week 1, treated patients rapidly gained motor ability and showed more than a 2-point improvement on the Overall Neuropathy Limitation Scale (ONLS), a tool used to assess limitations in everyday activities of the upper and lower limbs
		&nbsp;</li>
</ul>
</li>
<li>New efficacy findings at Week 26 also demonstrated that the benefit of tanruprubart was durable, with twice the number of treated patients having no limitations on the ONLS compared to placebo 
	&nbsp;</li>
<li>The new findings build upon previously reported Phase 3 trial results that showed an improvement in the primary endpoint of GBS-DS at Week 8, as well as that twice the number of patients treated with tanruprubart fully recovered to normal (GBS-DS = 0) at Week 26, compared to placebo</li>
<li>Treatment with tanruprubart enabled patients to walk independently and be off ventilation (for those requiring it) approximately a month earlier 
	&nbsp;</li>
<li>Patients treated with tanruprubart also spent approximately a week less time in intensive care 
	&nbsp;</li>
<li>Tanruprubart was well tolerated, with no new safety signals or off-target effects&nbsp;&nbsp; 
	&nbsp;</li>
</ul>
Results of the Phase 3 trial are reinforced by a <a href="https://www.globenewswire.com/Tracker?data=DxAw4ku8cSbOSU8IpAbXSnQebYzOh3uqzn1O3X3DAQ9QupIsKD0oAQjbOyBdFTXfJaxflqrBl2gQtSgQEk4RZro0rXvfA_-eHFpk0HFzz80uO8NLXCzlKFXU3MbdyLsggV9qslnoTuGnn5dHLlx2AgLjBz-Ku1vmrFfFjlbIDe39jle2tfy5ITlJtuumWrThfj1vKBZ9DQQxzjisskKZIDLbcSA6S0DNe9mZyc9-SGRHb8yXyks2UOoj4qiYhYjT">Real World Evidence (RWE) study</a>&nbsp;that matched tanruprubart-treated patients from the pivotal Phase 3 study with a Western world patient population treated with current standards of care, intravenous immunoglobulin (IVIg) or plasma exchange (PE). In the RWE study, tanruprubart showed a rapid increase in muscle strength with more complete recovery over IVIg or PE, consistent with benefits shown in the Phase 3 trial.&nbsp;The RWE study is planned for presentation at upcoming conferences.

Biotech

General

ANNX

Annexon Says Tanruprubart Met The Primary Endpoint; Demonstrates Rapid, Durable Recovery and Superior Efficacy In First Placebo-Controlled Phase 3 GBS Trial, Showing Significant Improvement In Motor Function, Mobility, and Disability Measures Over Placebo With No New Safety Signals

WIIM

Peabody Energy shares are trading after President Trump announced he signed an executive order to strengthen the electric grid.

Citigroup analyst Ariel Rosa maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Buy and lowers the price target from $130 to $95.

TFII

Citigroup Maintains Buy on TFI International, Lowers Price Target to $95

Citigroup analyst Ariel Rosa maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $498 to $435.

SAIA

Citigroup Maintains Buy on Saia, Lowers Price Target to $435

<a href="https://www.youtube.com/watch?v=cB6d0H3mSNA">https://www.youtube.com/watch?v=cB6d0H3mSNA</a>

Macro Economic Events

Politics

Economics

Trump Administration Aide Says First Executive Order Will Direct All Agencies To End All Discriminatory Policy Against Coal Industry; Says Trump Signs Executive Order On Coal; Says Second Order Imposes Moratorium That Would Shut Coal Plants; Says Third Order On Grid Reliability; Says Fourth Order Deals With Democratic States That Have Policies Against Coal

Citigroup analyst Ariel Rosa maintains RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) with a Neutral and lowers the price target from $23 to $15.

Citigroup Maintains Neutral on RXO, Lowers Price Target to $15

Citigroup analyst Ariel Rosa maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Buy and lowers the price target from $298 to $259.

Citigroup Maintains Buy on Norfolk Southern, Lowers Price Target to $259

President Donald Trump on Tuesday unveiled sweeping plans to revive U.S. coal production to meet the nation's rising energy demands, marking a dramatic policy reversal from the climate-focused agendas of the Biden <a href="https://www.benzinga.com/topic/donald-trump">and Obama administrations.</a>
Meanwhile, Wall Street plunged deeper into negative territory as escalating tariff tensions with China reignited fears of a global economic slowdown.
"We're ending Joe Biden's war on beautiful clean coal once and for all," Trump declared. "We're going to reopen those plants, put miners back to work, and get approvals very fast."
Trump's order directs federal agencies to fast-track mining permits, slash environmental regulations, and expand coal leases on federal lands.
"Pound for pound, coal is the single most reliable, durable, secure, and powerful form of energy on Earth," the president added.
According to the U.S. Energy Information Administration, coal production in 2023 totaled 578 million short tons, less than half the 1.17 billion short tons produced at its peak in 2008. 
The decline, the EIA noted, has been driven by rising costs, tougher environmental rules, and increased competition from natural gas and renewables.
&#8220;We&#8217;ll be signing a bill to unleash the might of our beautiful clean coal industry in this country,&#8221; Trump said.
Shares of Peabody Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>), the largest private-sector coal company in the world, rose 9% in after-hours trading, and Warrior Met Coal Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCC#NYSE">HCC</a>) rose 6.5%.
<h3 class="wp-block-heading">Wall Street Selloff Deepened</h3>
While Trump was touting coal's comeback, Wall Street was in full-blown retreat. 
Major indexes erased hefty morning gains in a volatile session that saw risk sentiment collapse after White House Press Secretary Karoline Leavitt confirmed Trump's 104% retaliatory tariff on Chinese imports would go live at 12:01 a.m. ET Wednesday.
"China made a mistake by retaliating, and the president is punching back harder," Leavitt said, ruling out any delay or exemption to the tariffs.
The news sent a jolt through financial markets, reversing a sharp morning rally and pushing the S&amp;P 500 index to its lowest levels in a year.
The S&amp;P 500 closed at 4,892, down 1.57%, after having surged as much as 3.7% earlier in the session.
The Nasdaq 100 ended the day at 17,104, falling 1.95% from the previous close, despite hitting a 4.1% intraday gain during the morning rally.
The Dow Jones Industrial Average finished at 37,663, shedding 0.8%, after climbing as much as 2.5% at its session peak.
<h3 class="wp-block-heading">Mega-Cap Tech: From Rally To Rout</h3>
Among the Magnificent Seven, losses were led by Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which closed down 5%, falling more than 9 percentage points from its intraday highs. 
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ended 4.9% lower, while Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) dropped 2.9%. 
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), which had surged more than 3% in morning trading, ended lower by 4%, signaling broad risk aversion toward chipmakers. AI darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) closed 1.4% lower.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44699965/biggest-tax-hike-since-1982-trumps-tariff-strategy-faces-harsh-economic-forecast">Biggest Tax Hike Since 1982? Trump&#8217;s Tariff Strategy Faces Harsh Economic Forecast</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Econ #s

Tech

AAPL

AMZN

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSLA

Trump Unleashes 'Beautiful Clean Coal' Policies As Wall Street Tanks, S&P 500 Hits 1-Year Low

Citigroup analyst Ariel Rosa maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Buy and lowers the price target from $193 to $164.

JBHT

Citigroup Maintains Buy on JB Hunt Transport Servs, Lowers Price Target to $164

Citigroup analyst Ariel Rosa maintains GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) with a Buy and lowers the price target from $51 to $45.

Citigroup Maintains Buy on GXO Logistics, Lowers Price Target to $45

Citigroup analyst Ariel Rosa maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Buy and lowers the price target from $305 to $267.

Citigroup Maintains Buy on FedEx, Lowers Price Target to $267

Citigroup analyst Ariel Rosa maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Buy and lowers the price target from $39 to $36.

Citigroup Maintains Buy on CSX, Lowers Price Target to $36

Citigroup analyst Ariel Rosa maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Buy and lowers the price target from $124 to $116.

CHRW

Citigroup Maintains Buy on C.H. Robinson Worldwide, Lowers Price Target to $116

Citigroup analyst Ariel Rosa maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Buy and lowers the price target from $91 to $84.

Citigroup Maintains Buy on Canadian Pacific Kansas, Lowers Price Target to $84

Aehr Test Systems  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) released its third-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/04/ac44700345/aehr-test-systems-reports-fiscal-2025-third-quarter-revenue-growth-and-solid-bookings-and-backlog">from the report. </a>
The Details: Aehr Test Systems reported quarterly earnings of seven cents per share, which beat the analyst consensus estimate of four cents. Quarterly revenue came in at $18.31 million, which beat the analyst consensus estimate of $17.76 million and is an increase over revenue of $7.56 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/25/04/44695907/elon-musk-calls-trump-trade-advisor-peter-navarro-dumber-than-sack-of-bricks-defends-tesla-as-the-most-american-made-cars">Elon Musk Calls Trump Trade Advisor Peter Navarro &#8216;Dumber Than Sack Of Bricks,&#8217; Defends Tesla As &#8216;Most American-Made Cars&#8217;&nbsp;</a>
Bookings were $24.1 million for the quarter. Backlog as of Feb. 28, 2025, was $18.2 million and effective backlog, including bookings since Feb. 28, 2025, was $21.8 million.
&#8220;We have been laser-focused on the initiatives we set out to expand our total addressable markets, diversify our customer base, and develop new products, capabilities and capacity to grow our business moving forward,&#8221; said Gayn Erickson, CEO of Aehr Test Systems.
&#8220;We are excited by the significant progress we&#8217;ve made this year in expanding into new key markets and unlocking new opportunities to attract customers and drive revenue growth, particularly in diversifying our markets and customers beyond our revenue concentration last fiscal year from silicon carbide (SiC) wafer level burn-in (WLBI),&#8221; Erickson added. 
Outlook:&nbsp;Aehr said it is temporarily withdrawing its fiscal 2025 financial guidance due to ongoing tariff uncertainty. 
AEHR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Aehr Test Systems shares were up 4.72% after-hours at $7.10 Tuesday.  
Read More:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase">&nbsp;Trump Slaps 25% Tariffs On Autos: What It Means For Your Next Car Purchase</a>&nbsp;</li>
</ul>
Image: Shutterstock

Earnings

After-Hours Center

Movers

AEHR

Aehr Test Systems Stock Climbs After Q3 Results: Details

Citigroup analyst Ariel Rosa maintains Canadian National Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) with a Buy and lowers the price target from $122 to $114.

Citigroup Maintains Buy on Canadian National Railway, Lowers Price Target to $114

<a href="https://www.bloomberg.com/news/articles/2025-04-08/kkr-nears-deal-to-buy-karo-for-more-than-2-5-billion" title="https://www.bloomberg.com/news/articles/2025-04-08/kkr-nears-deal-to-buy-karo-for-more-than-2-5-billion">https://www.bloomberg.com/news/articles/2025-04-08/kkr-nears-deal-to-buy-karo-for-more-than-2-5-billion</a>

'KKR Nears Deal To Buy Karo Healthcare For More Than €2.5 Billion' - Bloomberg News

Citigroup analyst Ariel Rosa maintains ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) with a Neutral and lowers the price target from $83 to $66.

ARCB

Citigroup Maintains Neutral on ArcBest, Lowers Price Target to $66

<a href="https://www.youtube.com/watch?v=cB6d0H3mSNA" title="https://www.youtube.com/watch?v=cB6d0H3mSNA">https://www.youtube.com/watch?v=cB6d0H3mSNA</a>

Global

President Trump Says Today I Signed Executive Order To Strengthen Electric Grid; I Instruct Energy Secretary To Save Arizona Coal Plant From Closure; Grant Immediate Relief To 47 Companies Operating Coal Plants; Making Them Available For Coal Production

Comments

Oriental Rise Holdings

Oriental Rise Holdings (ORIS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL